Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?

Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries. Allopurinol, a drug used safely in the treatment of gout for many years, has been found to dramatically reduce "oxidative stress". It is therefore hoped that it also reduce the thickened heart muscle and stiffened arteries. If it did, it is likely to reduce the appallingly high cardiac death rate in this group of kidney disease patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Disease Bronchial Diseases Bronchiolitis Bronchiolitis Obliterans Bronchiolitis Obliterans Syndrome Bronchitis Cardiomegaly Cardiovascular Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Graft vs Host Disease Heart Diseases Hypertrophy Hypertrophy, Left Ventricular Immune System Diseases Kidney Diseases Left Ventricular Hypertrophy Lung Diseases Lung Diseases, Obstructive Male Urogenital Diseases Organizing Pneumonia Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Division of Medicine and Therapeutics, Ninewells Hospital & Medical School

Dundee, DD1 9SY, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CKD stage 3
Echo LVH

Exclusion criteria

Known heart failure
Patients already on Allopurinol
Patients with gout
Patients with hepatic disease
Contraindications to MRI, including severe claustrophobia
Current immunosuppressive therapy, chlorpropamide, theophylline, 6- mercaptopurine
Malignancy or other life threatening disease
Pregnancy or lactating women
Patients unable to provide written consent

Treatment and study plan

Placebo

Drug

1 capsule, orally for 9 months

Allopurinol

Drug

Allopurinol 300 mg once/day orally, 9 months

Primary outcomes

Primary objective is to see if Allopurinol reduces left ventricular hypertrophy (LVH) in this group of CKD patients

Time frame: 9 months

Secondary outcomes

Secondary objective is to see if Allopurinol reduces endothelial dysfunction in this group of CKD patients

Time frame: 9 months

Sponsors and collaborators

Lead sponsor

A. D. Struthers

Other

Registry information

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2010
First posted: Jun 3, 2008
Registry last updated: Nov 3, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed